Dupilumab SAR231893
LPS15991
Approved small_molecule completed
Quick answer
Dupilumab SAR231893 for Atopic Dermatitis is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Atopic Dermatitis
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed